1st Quarter - Report

GILEAD SCIENCES, INC. for GILEAD SCIENCES INC

Period 1st Quarter 2012 Filed Apr 20, 2012 Signed by Joseph Grogan, Director, Government Affairs

Official filing
Firm
GILEAD SCIENCES, INC.
Client
GILEAD SCIENCES INC
Income
—
Expenses
$560,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Domestic HIV Policy issues: HIV/AIDS Technology Transfer and Patent Rights; HIV Testing and Treatment; Federal Employees Health Benefits and Program Coverage for Routine HIV screening; HIV/AIDS Funding. Health Care Reform ( Patient Protection and Affordable Care Act - P.L.111-148; Health Care and Education Affordability Reconciliation Act - P.L.111-152); Hepatitis B Funding for Screening and Linkage to Care Programs; Hepatitis C Policy; Medicare Part D and Dual Eligibles; International HIV and Health issues; PEPFAR; International Trade and Intellectual Property Rights issues.

LobbyistCovered position, as disclosed
JOSEPH GROGAN —
CRISTIN LIS —
REKHA RAMESH —

Contacted: White House Office; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); U.S. Agency for International Development (USAID); Food & Drug Administration (FDA); SENATE; Commerce, Dept of (DOC); Veterans Affairs, Dept of (VA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.